Protalix BioTherapeutics, Inc.
PLXNYSE
$2.38
↑ +3.0%Jul 17 close · end-of-day
Price
1Y↑ +66.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$197.7M
Enterprise Value
$156.7M
P/E
12.5
P/S
2.6
P/B
2.9
EV/EBITDA
7.3
PEG
—
FCF Yield
6.6%
Dividend Yield
—
Revenue (TTM)
$76.4M
Net Income (TTM)
$15.3M
Free Cash Flow (TTM)
$13.0M
Gross Margin
—
Operating Margin
25.9%
Net Margin
20.1%
ROE
22.8%
ROIC
60.1%
Debt / Equity
—
Net Cash
$41.0M
Return 1Y
+58.7%
Company profile
Protalix BioTherapeutics, Inc. focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials.
- CEO
- Dror Bashan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Headquarters
- New Jersey
- Website
- protalix.com
Management & directors
- Bashan DrorPRESIDENT AND CEO
- Naos YaronSr. VP, Operations
Roles derived from SEC Form 4 filings.
Earnings
PLX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$33.8M↑ +233.7%
Diluted EPS$0.22↓ -540.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $62.9M | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $2.7M | -$20.5M | -$13.0M | $10.5M | $3.9M | -$5.5M |
| Net income | -$6.5M | -$27.6M | -$14.9M | $8.3M | $2.9M | -$6.6M |
| Diluted EPS | -$0.22 | -$0.62 | -$0.31 | $0.09 | $0.04 | -$0.08 |
| Operating cash flow | -$26.1M | -$10.3M | -$25.0M | -$1.3M | $8.7M | -$12.0M |
| Free cash flow | -$26.8M | -$11.7M | -$25.6M | -$2.5M | $7.4M | -$13.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 4.3% | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% |
| Net margin | -10.4% | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $18.0M | $18.2M | $10.1M | $15.7M | $17.9M | $9.1M | $33.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.4M | $4.0M | $7.2M | -$4.1M | $1.2M | $2.1M | -$4.7M | $21.1M |
| Net income | -$2.2M | $3.2M | $6.5M | -$3.6M | $164,000.00 | $2.4M | -$5.5M | $18.3M |
| Diluted EPS | -$0.03 | $0.03 | $0.10 | -$0.05 | $0.00 | $0.03 | -$0.06 | $0.22 |
| Operating cash flow | -$3.6M | $4.1M | $4.0M | -$5.1M | -$5.2M | -$3.7M | $2.0M | $22.0M |
| Free cash flow | -$3.8M | $4.0M | $3.6M | -$5.4M | -$5.7M | -$4.2M | $1.6M | $21.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -18.0% | 22.2% | 39.6% | -41.0% | 7.5% | 11.9% | -51.1% | 62.7% |
| Net margin | -16.4% | 18.0% | 35.6% | -35.8% | 1.0% | 13.2% | -60.3% | 54.3% |
Company news
May 14, 2026
May 13, 2026
- 67d agoProtalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...finance.yahoo.com
- 68d agoTranscript: Protalix BioTherapeutics Q1 2026 Earnings Conference Callfinance.yahoo.com
- 68d agoProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business Resultsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-19 | Bashan Dror· PRESIDENT AND CEO | Buy | 56,000 | $1.81 | $101,360.00 | filing |
| 2025-11-18 | Bar-Shalev Amos | Sale | 168 | $1.87 | $314.16 | filing |
| 2025-09-03 | Melincoff Gwen A | Award | 7,500 | — | — | filing |
| 2025-09-03 | Forster Eliot | Award | 7,500 | — | — | filing |
| 2025-09-03 | Boudes Pol F | Award | 7,500 | — | — | filing |
| 2025-09-03 | Schwartz Aharon | Award | 7,500 | — | — | filing |
| 2025-09-03 | Elze Christian | Award | 7,500 | — | — | filing |
| 2025-09-03 | Ben Zvi Shmuel | Award | 7,500 | — | — | filing |
| 2025-09-03 | Bar-Shalev Amos | Award | 7,500 | — | — | filing |
| 2025-09-03 | Naos Yaron· Sr. VP, Operations | Award | 25,000 | — | — | filing |
| 2025-09-03 | Bashan Dror· PRESIDENT AND CEO | Award | 195,000 | — | — | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.